New Anticancer Drugs

Front Matter....Pages I-XI
Introduction of U.S.-Japan Joint Meeting on Phase I and II Clinical Trials....Pages 1-3
The New NCI Screen and Its Implications for Clinical Evaluation....Pages 5-20
The National Cancer Institute’s Natural Products Antineoplastic Development Program....Pages 21-44
Methodology of Phase I Study in Japan....Pages 45-51
Methodology of Phase II Clinical Trial in Cancer....Pages 53-60
Phase II Study of Antineoplastic Agents in Japan....Pages 61-65
Clinical Strategy for Evaluation of Anthracycline Analogues....Pages 67-73
Preliminary Clinical Study of Aclacinomycin A....Pages 75-81
Preclinical and Clinical Studies on Chlorozotocin, a New Nitrosourea with Decreased Bone Marrow Toxicity....Pages 83-89
Continuation of Phase II Study of 1-(4-Amino-2-Methylpyrimidine-5-yl)-Methyl-3-(2-Chloroethyl)-3-Nitrosourea Hydrochloride (ACNU)....Pages 91-106
Review of Experimental Studies on Nitrosourea Derivatives in Japan....Pages 107-117
The Clinical Evaluation of Analogues, IV. Nitrosoureas....Pages 119-123
Review of a New Antimetabolic Agent 1-Hexylcarbamoyl-5-Fluorouracil (HCFU)....Pages 125-132
Review of a New Antimetabolic Agent, 1,3-Bis(Tetrahydro-2-Furanyl)-5-Fluoro-2,4-Pyrimidinedione (FD-1)....Pages 133-145
Effect and Mode of Action of N 4 -Behenoyl- β -D-Arabinofuranosylcytosine....Pages 147-151
Strategy for Evaluation of a New Antitumor Agent in the Treatment of Breast Cancer....Pages 153-157
Current Status of Breast Cancer Chemotherapy in Japan....Pages 159-166
Present Status of Lung Cancer Chemotherapy in Japan....Pages 167-177
Clinical Strategies in the Chemotherapy of Gastrointestinal Cancer....Pages 179-185
Clinical Evaluation Strategy in Specific Disease Types — Clinical Study of Gastrointestinal Cancer Chemotherapy in One Institute of Japan....Pages 187-202
A Review of Therapeutic Strategies for Phase I-II Trials in Genitourinary Cancer....Pages 203-210
Recent Results of Using a Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Metastatic Cervical Cancer....Pages 211-217
Pharmacologic and Clinical Studies of N 4 -Behenoyl-1-Beta-D-Arabinofuranosylcytosine....Pages 219-229
Back Matter....Pages 231-232